Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study

被引：1
|
作者：
Sternberg, C. N. [1 ,2 ]
Scher, H. I. [3 ]
Molina, A. [4 ]
North, S. [5 ]
Mainwaring, P. [6 ,7 ]
Hao, Y. [8 ]
Gagnon, D. [9 ]
Kheoh, T. [4 ]
Haqq, C. M. [4 ]
de Bono, J. [10 ,11 ]
机构：
[1] San Camillo Hosp, Dept Med Oncol, Rome, Italy
[2] Forlanini Hosp, Dept Med Oncol, Rome, Italy
[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[4] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
[5] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[6] Haematol Clin Australasia, Milton, MA, Australia
[7] Oncol Clin Australasia, Milton, MA, Australia
[8] Johnson & Johnson Pharmaceut Serv, Global Strateg Mkt & Market Access, Raritan, NJ USA
[9] Thomson Reuters, Strateg Consulting Healthcare, Santa Barbara, CA USA
[10] Inst Canc Res, Sutton, Surrey, England
[11] Royal Marsden Hosp, Med Sect, Sutton, Surrey, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71966-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [1] Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study
    Harland, S.
    de Bono, J. S.
    Haqq, C. M.
    Staffurth, J. N.
    Hao, Y.
    Gagnon, D.
    Liu, C.
    Sternberg, C. N.
    Molina, A.
    Scher, H. I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S484 - S484
  • [2] Impact of prior antiandrogen exposure on clinical outcomes in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Bellmunt, J.
    Yu, M. K.
    Kheoh, T.
    Taplin, M. E.
    Davis, I. D.
    Schnjvers, D.
    Protheroe, A.
    Molina, A.
    De Bono, J. S.
    Scher, H. I.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S695 - S695
  • [3] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
  • [4] Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel
    Fizazi, K.
    Scher, H. I.
    Molina, A.
    Logothetis, C. J.
    Jones, R. J.
    Staffurth, J. N.
    Li, J.
    Kheoh, T.
    Haqq, C. M.
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S483 - S484
  • [5] Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D)
    Montgomery, Robert B.
    San Kheoh, Thian
    Molina, Arturo
    Li, Jinhui
    Bellmunt, Joaquim
    Ryan, Charles J.
    Namphuong Tran
    Loriot, Yohann
    Efstathiou, Eleni
    Scher, Howard I.
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)
    Goodman, Oscar B.
    Flaig, Thomas W.
    Molina, Arturo
    Mulders, Peter
    Suttmann, Henrik
    Li, Jinhui
    Kheoh, Thian San
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [7] Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.
    Logothetis, C.
    De Bono, J. S.
    Molina, A.
    Basch, E. M.
    Fizazi, K.
    North, S. A.
    Chi, K. N.
    Jones, R. J.
    Goodman, O. B.
    Mainwaring, P. N.
    Sternberg, C. N.
    Gagnon, D. D.
    Dhawan, R.
    Rothman, M.
    Hao, Y.
    Liu, C. S.
    Kheoh, T. S.
    Scher, H. I.
    Haqq, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)
    Goodman, Oscar B.
    Chi, Kim N.
    Molina, Arturo
    Logothetis, Christopher
    Jones, Robert J.
    Staffurth, John
    North, Scott A.
    Vogelzang, Nicholas J.
    Saad, Fred
    Mainwaring, Paul N.
    Harland, Stephen John
    Li, Jinhui
    San Kheoh, Thian
    Haqq, Christopher M.
    Scher, Howard I.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)
    Chi, Kim N.
    Scher, Howard I.
    Molina, Arturo
    Logothetis, Christopher
    Jones, Robert J.
    Staffurth, John
    North, Scott A.
    Vogelzang, Nicholas J.
    Saad, Fred
    Mainwaring, Paul N.
    Harland, Stephen John
    Li, Jinhui
    San Kheoh, Thian
    Haqq, Christopher M.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] Improved Overall Survival (OS) in patients with metastatic Castration Resistant Prostate Cancer (mCRPC) progressing after docetaxel-based chemotherapy: Results from the phase III study COU-AA-301 with abiraterone acetate
    Ohlmann, C. H.
    Stoeckle, M.
    Pfister, D.
    de Bono, J. S.
    Molina, A.
    Frohn, C.
    Kheoh, T.
    Haqq, C. M.
    Scher, H., I
    Wirth, M.
    Suttmann, H.
    Miller, K.
    ONKOLOGIE, 2011, 34 : 9 - 10
12345